ReviewDrugs2021
Hetrombopag: First Approval.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 53 citations in OpenAlex.
- Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial.Journal of hematology & oncology · 2026Trial
- Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.American journal of hematology · 2026Trial
- Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.Blood cancer journal · 2025Trial
- Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.Annals of hematology · 2024Trial
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.Annals of medicine · 2023Trial
- Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study.Annals of hematology · 2022Trial
- Preliminary experience with oral thrombopoietin-receptor agonists, primarily hetrombopag, in pediatric immune thrombocytopenia: a pilot single-center retrospective report.Translational pediatrics · 2026Article
- Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.Annals of hematology · 2026Article
- Evolving Patterns of TPO-RA Use in Children: A Decade of Single-Centre Experience and Narrative Review.International journal of molecular sciences · 2026Review
- Hematopoiesis could be improved by correcting aberrant bone marrow macrophages polarization in aplastic anemia patients.Science China. Life sciences · 2026Article
- Longitudinal clinical and preclinical studies identify hetrombopag as a potent chelator for systemic iron overload.HemaSphere · 2026Article
- MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies.Frontiers in medicine · 2026Review
- Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support.Frontiers in oncology · 2026Article
- Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.Research and practice in thrombosis and haemostasis · 2026Review
- Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report.Frontiers in oncology · 2026Article
- Romiplostim for cancer treatment-induced thrombocytopenia in acute promyelocytic leukemia: a case report.Frontiers in oncology · 2026Article
- Hetrombopag for enhancement of platelet engraftment after allogeneic hematopoietic stem cell transplantation: A single-center experience.Therapeutic advances in hematology · 2026Article
- Hetrombopag for thrombocytopenia induced by concurrent or sequential chemoradiotherapy in patients with solid tumors: a double-cohort trial.BMC cancer · 2025Article
- Umbilical cord blood infusion in the treatment of aplastic anemia: A single center prospective study.Scientific reports · 2025Article
- Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITP.Annals of hematology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hetrombopag (Hengqu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.